There were 1,870 press releases posted in the last 24 hours and 439,438 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image